Beruflich Dokumente
Kultur Dokumente
INTRODUCTION:
* It is common gynaecological tumour continue to kill more women than all other gynaecological cancer * In England the incidents of ovarian cancer 1.4 higher than cervical and endometrial cancer but lower than breast cancer 7.1% * Eventually 80 to 85% of women with ovarian cancer die * Most ovarian cancer as epithelial in origin and incidence increase risk with age.
Germ cell tumour rare and occur mainly in children and young women. * Survival rater 5 years in 60% of stage I disease ovarian malignancy. Histopathology and Classification of ovarian mass. * Ovarian mass Physiological Neoplastic Benign Malignant
Histological classification of ovarian Tumour Epithelial Tumour Serous Tumour Mucinous Tumour Endometrial Tumour Clear Tumour Mixed Tumour Undifferentiated and Unclassified Tumour
* * * * * *
Epithelial Tumour Arise from surface epithelium of ovary account from 60-65 % of ovarian tumour and approximately 90% are malignant. Benign border line malignant Sex cord stromal tumour Derived from sex cord & Stroma of ovary Account approximately 8% of all ovarian tumour
Germ Cell Tumour = - Arise from germ cells - Account from 30% of ovarian tumour in the form of mature cyst tertoma (Dermoid Cysts) and 1 3 % of ovarian malignancy and represent 60% of ovarian cancer in children and adolescents.
Epithelial ovarian tumour *common bilateral *Serous most common 40 50%. *Mucinous 10% large size associated with pseudomyxoma ovari
* Endometrial ovarian cancer: account for 20% of epithelial tumour. 10% associated with endometrial cancer. * Brenner tumour very small proportion - 99% Benign * Clear Cell cancer Account from 5 10% 10% - Worse prognosis * Mixed epethilium ovarian tumour
Immature Teratoma:
* 2nd commonest germ cell malignancy. * Account for 20% ovarian cancer in female under 20 years of age. * Unilateral * classified according to differentiation and quantity of immature tissue.
Embryonic Markers:
* Yolk sac tumour AFP - (rare tumor)
* Ovarian choriocarcinoma secret BHCG (rare tumour) * Normal level does not exclude diagnosis. * Teratoma & dysgemenoma does not secret this tumor marker.
Krukenberg Tumour: Bilateral enlarged ovaries * Ovarian metastatic tumour from gastric or colon cancer. * Microscopic assessment signet ring cells.
Eitology:
* Environmental Factors: Unknown High fat diet Perineal dusting with talcum powder Risk of caffeine intake and radiation unclean. - Role of certain viral infection (Mumps, rubella, influenza) inconclusive results.
This suggest continous ovulation is important factor. * Using of ovulatory stimulants and subsequent development of epithelial ovarian cancer is currently lacking. * Heriditary factors not more than 10% of all ovarian cancer. * BRCAI responsible for 5% of ovarian cancer in young women < 40 years.
Clinical Signs:
* Supraclavicular, axillary, inguinal lymph nodes. * * * * Breast examination Chest examination pleural effusion Abdominal examination liver size Pelvic & rectal examination Irregular solid mass suggestive of malignancy.
INVESTIGATIONS
-
For blood count Urea and electrolyte Liver function test Tumor marker Ca 125 AFP & B-HCG CEA U/S for pelvis, kidney and liver MIR CT Scan Endometrial biopsy Endoscopy
89.9 84.7 80
III IIIa
58.5
As for stage I/II but also with peritoneal Implants outside pelvis or with positive retroperitoneal lymph nodes Histologically confirmed microscopic seeding of abdominal peritoneal surfaces and negative retroperitoneal lymph nodes Histologically confirmed implants of abdominal peritoneal surfaces <2cm and negative retroperitoneal lymph nodes Histologically confirmed implants of abdominal peritoneal surfaces <2 cm or positive retroperitoneal lymph nodes Distant metastases (including liver parenchyma/positive pleural fluid cytology)
IIIb
39.9
IIIc
28.7
IV 16.8
Metastatic ovarian spread: * Direct tubes uterus - bladder * Trascoelmic along peritoneal surface. * Lymphatic spread pelvic and para aortic lymph nodes. * Haematogenous spread - liver - lung
Technique for Surgical Staging: * Midline incision adequate access for surgical staging and full inspections. 1. Sending ascites or peritoneal washing 2. Performing total hystrectomy and bilateral salpingo ophorectomy. 3. Omentectomy 4. Peritoneal biopsy all suspicious area. 5. Diaphragmatic biopsy or scraping. 6. Sampling of pelvic and a paraaortic lymph nodes.
Chemotherapy:
* Standard adjuvant depending involve IV chemotherapy single agent active in epithelial ovarian cancer. Include: Alkalizing agent (cyclophosophomide) - platinuim compound (cisplatin) - taxanes (paclitaxel) - paclitaxel and platinum became new standard of care in advanced ovarian cancer. - pallative surgery bowel obstruction involve bowel resection and intestinal bypass.
Sex cord stromal tumour: Surgery is the gold standard but early stage can be managed by unilateral oophorectomy and endometrial biopsy when fertility is important.
- Cooperation with general surgeon and experience in field of chemotherapy and radiotherapy. - Treatment by radiotherapy only for pallation. - CA 125 is usually raised in advanced ovarian cancer and used to assess response to chemotherapy.
Chemotherapy:
- Act by inhibiting cell deviation * Alkalyting agent preventing replication of DNA - cyclophosphoamide - Chloraambucil
*Antimitotic antibiotic Prevent DNA protein synthesis actinomycin D Antimetabolites: Preventing the synthesis of nucleoprotein Methotrexate: Other Non Alkylating agent * Cisplatin -Carboplatin * Taxanes Paclitaxel
Toxicity: Bone marrow depression gastrointestinal neurotoxic nephrotoxic alopecia candiatoxic liver failure regular check up for marrow and liver function
Prognosis for epithelial ovarian cancer Stage I II III IV 5 years survival 60 70% 40 - 50% 5 - 10% nil
5 years 90 95% 15 years survival 70-85%- For serous tumour 5-10% for mucinous Chemotherapy is effective in the in frequent germ cell tumour